BIOLASE (NASDAQ:BIOL) Earns “Speculative Buy” Rating from Benchmark

BIOLASE (NASDAQ:BIOL)‘s stock had its “speculative buy” rating reiterated by equities researchers at Benchmark in a research note issued on Monday, Benzinga reports. They presently have a $0.40 price objective on the medical technology company’s stock.

Other equities analysts also recently issued research reports about the stock. Maxim Group downgraded shares of BIOLASE from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 24th. StockNews.com began coverage on BIOLASE in a report on Thursday. They set a “sell” rating on the stock.

BIOLASE Trading Up 7.3 %

Shares of NASDAQ BIOL traded up $0.00 during trading on Monday, reaching $0.05. The company had a trading volume of 135,973 shares, compared to its average volume of 3,130,162. BIOLASE has a twelve month low of $0.04 and a twelve month high of $6.70. The stock has a 50-day moving average price of $0.10 and a two-hundred day moving average price of $0.18. The stock has a market capitalization of $1.82 million, a PE ratio of 0.00 and a beta of 0.71.

BIOLASE (NASDAQ:BIOL) last released its earnings results on Monday, May 13th. The medical technology company reported ($0.36) earnings per share (EPS) for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The firm had revenue of $10.13 million during the quarter.

Hedge Funds Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.79% of the company’s stock.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.